Sankala Group
IMVT icon

Sankala Group’s Immunovant IMVT Stock Holding History

Sankala Group’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.2K Buy
300
+150
+100% +$5.91K 0.01% 377
2026
Q2 		$6.53K Hold
150
– – ﹤0.01% 444
2026
Q1 		$3.71K Hold
150
– – ﹤0.01% 453
2025
Q4 		$4.16K Buy
+150
New +$3.34K ﹤0.01% 460

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Sankala Group's IMVT Position: Q3 2026 in Review

Sankala Group increased its Immunovant (IMVT) stake by 100% in Q3 2026, buying an estimated $5.91K and bringing the position to 300 shares worth $10.2K. The position accounts for 0.01% of the portfolio, ranked #377.

Sankala Group first reported a position in IMVT in Q4 2025 and has held it in 4 quarters since. 101 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

  • Sankala Group held 300 shares of Immunovant worth $10.2K as of Q3 2026.
  • Sankala Group bought 150 Immunovant shares in Q3 2026, an estimated $5.91K.
  • Immunovant made up 0.01% of Sankala Group's portfolio in Q3 2026, its #377 holding.
  • Sankala Group first reported a position in Immunovant in Q4 2025 and has held it in 4 quarters since.
  • 101 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on Sankala Group's 13F filing for Q3 2026, filed 9 Nov 2026.